ZYNE - Zynerba delaying release of late-stage top-line results for Fragile X syndrome candidate

• Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) says top-line data for a phase 3 trial of its Fragile X syndrome treatment Zygel will now come in H1 2024 instead of H2 2023.
• The company said that high rates of respiratory syncytial virus and influenza as well as the continued impact of COVID-19 among participants and personnel has led to a higher than expected cancellations of initial screening visits.
• Despite the adjustment, Zynerba ( ZYNE ) expects to have enough cash to fund operations through mid 2024.
• Zygel is a clear gel containing cannabidiol.
• Seeking Alpha's Quant Rating views Zynerba ( ZYNE ) as a hold with high marks for valuation and revisions .

For further details see: